Figures & data
Table 1. LAMA/LABA medications available in the USA.
Figure 1. Summary of evidence for LAMA/LABA versus LAMA and ICS/LABA.
*Few studies have assessed exacerbation risk with LAMA/LABA versus ICS/LABA, and the available data do not consistently favor either class. FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SGRQ, St George’s Respiratory Questionnaire; TDI, Transition Dyspnea Index
![Figure 1. Summary of evidence for LAMA/LABA versus LAMA and ICS/LABA.](/cms/asset/78111bb9-d7fb-467e-b6ab-5622da7ca056/ipgm_a_1702834_f0001_b.gif)